brincidofovir (Tembexa) Report issue

Small molecule Orphan Drug FDA Approved FDA Fast Track FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Brincidofovir, sold under the brand name Tembexa, is an antiviral drug used to treat smallpox. Brincidofovir is a prodrug of cidofovir. Conjugated to a lipid, the compound is designed to release cidofovir intracellularly, allowing for higher intracellular and lower plasma concentrations of cidofovir, effectively increasing its activity against dsDNA viruses, as well as oral bioavailability.   Wikipedia

  • SMILES: CCCCCCCCCCCCCCCCOCCCOP(=O)(O)CO[C@H](CO)CN1C=CC(=NC1=O)N
  • InChIKey: WXJFKKQWPMNTIM-VWLOTQADSA-N
  • Mol. Mass: 561.7
  • ALogP: 5.25
  • ChEMBL Molecule:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No
brincidofovir | cidofovir hexadecyloxypropyl ester | cmx001 | cmx 001 | cmx-001 | hdp-cdv | hexadecyloxypropyl cidofovir

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue